newsfilter
← Latest News
GlobeNewswire·

Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update

KA

Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering